The association between residual tumor volume after primary cytoreduction and survival was less consistent in patients with low-grade serous ovarian carcinoma (LGSOC) compared with other histology ...
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia ...
Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group. This is an ASCO ...
“Our results indicate that the primary treatment modality should not be used to exclude patients from secondary surgery,” said MSK gynecologic oncology fellow Beryl Manning-Geist, MD, co-lead author ...
Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera. Cytoreduction is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results